Skip to main content

Table 1 Surface interaction between npGG aAPCs and murine CD4+ T cells

From: Highly tailorable gellan gum nanoparticles as a platform for the development of T cell activator systems

Experimental conditions

µg

%

Day 1

Day 5

npGG

1

1.68 (0.36)

1.1 (1.13)

10

2.26 (0.71)

1.63 (1.39)

50

2.4 (1.09)

1.65 (0.96)

100

1.8 (0.53)

1.9 (1.50)

npGG 10 µg α-CD3

1

3.71 (2.09)

8.4 (10.03)

10

10.65 (9.88)

8.57 (6.53)

50

22.82 (16.67)

19.53 (18.05)

100

30.79 (2.09)

19.53 (18.05)

npGG-NaV 10 µg α-CD3

1

3.68 (2.16)

4.98 (3.52)

10

12.3 (9.21)

11.57 (7.86)

50

37.57 (33.04)

19.8 (15.73)

100

39.21 (31.75)

33.34 (23.23)

npGG 20 µg α-CD3

1

6.65 (1.91)

6.8 (5.24)

10

22.83 (8.35)

17.23 (4.46)

50

38.48 (15.79)

40.4 (30.74)

100

70.6 (0.60) **

44.1 (18.29)

npGG-NaV 20 µg α-CD3

1

9.7 (1.67)

8.55 (3.61)

10

35.5 (6.79)

28.13 (5.54)

50

51.45 (17.75) ***

53.65 (8.33) **

100

61.53 (8.04) ***

61.1 (8.08) ***

  1. Flow cytometry data of murine splenocytes incubated with varying concentrations of npGG aAPCs over 1 and 5 days in the percentage of CD4+ T cells positive for nanoparticles. CD4+ T cells were labeled with AF647 while npGG-α-CD3 were labelled with AF488 anti-rat IgG. Double positive labeling was translated in the % of CD4+ T cells with surface bound npGG-α-CD3. Quantitative results are expressed as the mean ± standard deviation where n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA with Kruskal–Wallis multiple comparison post-test
Back to article page

Biomaterials Research

ISSN: 2055-7124

Contact us